Improving RNA-based medicines for inherited retinal degeneration
Optimizing Enhanced Hammerhead Ribozymes for Retinal Nucleic Acid Therapeutics
Developing new RNA molecules that can cut faulty eye genes to help people with inherited retinal degenerations like autosomal dominant retinitis pigmentosa.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11332629 on NIH RePORTER |
What this research studies
Researchers are improving a type of catalytic RNA (enhanced hammerhead ribozymes) that can cut disease-causing messages in retinal cells. They aim to make versions that work inside photoreceptors at normal cellular conditions and that could be given as injectable drugs without viral vectors. Lab and animal tests will measure how quickly and specifically these molecules cut target RNA and whether they protect or restore retinal cells. If the molecules perform well and are safe, the work could lead to future human trials for several inherited retinal diseases.
Who could benefit from this research
Good fit: People with inherited retinal degenerations such as autosomal dominant retinitis pigmentosa from RHO or similar mutations who are interested in novel nucleic-acid treatment approaches.
Not a fit: People with very advanced, end-stage vision loss or retinal disease caused by mechanisms not addressed by RNA knockdown and replacement are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this could produce injectable RNA therapies that reduce harmful mutant gene products and help preserve vision in people with inherited retinal degeneration.
How similar studies have performed: Older hammerhead ribozymes partially rescued mutant RHO in rodent models and intravitreal antisense drugs have shown clinical success, but this specific enhanced ribozyme strategy is relatively new.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Sullivan, John M. — State University of New York at Buffalo
- Study coordinator: Sullivan, John M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.